Pre-made Regavirumab benchmark antibody (Whole mAb, anti-HCMV (human cytomegalovirus) envelope glycoprotein B (gB) [Human betaherpesvirus 5] therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-HCMV (human cytomegalovirus) envelope glycoprotein B (gB) [Human betaherpesvirus 5] therapeutic antibody (Pre-made Regavirumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Regavirumab is a human monoclonal antibody against infections with cytomegalovirus.[1]
| Products Name (INN Index) | Pre-Made Regavirumab Biosimilar, Whole Mab: Anti-Hcmv (Human Cytomegalovirus) Envelope Glycoprotein B (Gb) [Human Betaherpesvirus 5] therapeutic antibody |
|---|---|
| INN Name | regavirumab |
| Target | HCMV (human cytomegalovirus) envelope glycoprotein B (gB) [Human betaherpesvirus 5] |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Teijin?Ltd. (Tokyo Japan) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | Human hybridoma |
| Previous Name | NA |
| Gm Offical Target Name | HCMV (human cytomegalovirus) envelope glycoprotein B (gB) [Human betaherpesvirus 5] |
| Package |
